Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib

被引：75

作者：

Krauss, Ronald M. ^{[1
]}

Wojnooski, Kathleen ^{[1
]}

Orr, Joseph ^{[1
]}

Geaney, J. Casey ^{[1
]}

Pinto, Cathy Anne ^{[2
]}

Liu, Yang ^{[2
]}

Wagner, John A. ^{[2
]}

Luk, Julie Mabalot ^{[2
]}

Johnson-Levonas, Amy O. ^{[2
]}

Anderson, Matt S. ^{[2
]}

Dansky, Hayes M. ^{[2
]}

机构：

[1] Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA

[2] Merck Sharp & Dohme Corp, Whitehouse Stn, NJ USA

来源：

JOURNAL OF LIPID RESEARCH | 2012年 / 53卷 / 03期

关键词：

cholesteryl ester transfer protein inhibitor; lipid; low density lipoprotein; ESTER TRANSFER PROTEIN; HIGH-DENSITY-LIPOPROTEIN; CHOLESTEROL EFFLUX; BLOOD-PRESSURE; RESIDUAL RISK; TORCETRAPIB; DISEASE; EVENTS; PLASMA; HDL;

D O I：

10.1194/jlr.M018010

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

We investigated the effects of the cholesteryl ester (CE) transfer protein inhibitor anacetrapib (ANA) on plasma lipids, lipoprotein subfraction concentrations, and lipoprotein composition in 30 healthy individuals. Participants (n = 30) were randomized to ANA 20 mg/day, 150 mg/day, or placebo for 2 weeks. Changes in concentration of lipoprotein subfractions were assessed using ion mobility, and compositional analyses were performed on fractions separated by density gradient ultracentrifugation. ANA 150 mg/day versus placebo resulted in significant decreases in LDL-cholesterol (26%) and apo B (29%) and increases in HDL-cholesterol (82%). Concentrations of medium and small VLDL, large intermediate density lipoprotein (IDL), and medium and small LDL (LDL2a, 2b, and 3a) decreased whereas levels of very small and dense LDL4b were increased. There was enrichment of triglycerides and reduction of CE in VLDL, IDL, and the densest LDL fraction. Levels of large buoyant HDL particles were substantially increased, and there was enrichment of CE, apo AI, and apoCIII, but not apoAII or apoE, in the mid-HDL density range. Changes in lipoprotein subfraction concentrations and composition with ANA 20 mg/day were similar to those for ANA 150 mg/day but were generally smaller in magnitude. The impact of these changes on cardiovascular risk remains to be determined.-Krauss, R. M., K. Wojnooski, J. Orr, J. C. Geaney, C. A. Pinto, Y. Liu, J. A. Wagner, J. Mabalot Luk, A. O. Johnson-Levonas, M. S. Anderson, and H. M. Dansky. Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. J. Lipid Res. 2012. 53: 540-547.

引用

页码：540 / 547

页数：8

共 30 条

[1] Effects of torcetrapib in patients at high risk for coronary events [J].

Barter, Philip J. ;

Caulfield, Mark ;

Eriksson, Mats ;

Grundy, Scott M. ;

Kastelein, John J. P. ;

Komajda, Michel ;

Lopez-Sendon, Jose ;

Mosca, Lori ;

Tardif, Jean-Claude ;

Waters, David D. ;

Shear, Charles L. ;

Revkin, James H. ;

Buhr, Kevin A. ;

Fisher, Marian R. ;

Tall, Alan R. ;

Brewer, Bryan .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2109-2122

[2] CONTROLLING THE FALSE DISCOVERY RATE - A PRACTICAL AND POWERFUL APPROACH TO MULTIPLE TESTING [J].

BENJAMINI, Y ;

HOCHBERG, Y .

JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 1995, 57 (01) :289-300

[3] Metabolic origins and clinical significance of LDL heterogeneity [J].

Berneis, KK ;

Krauss, RM .

JOURNAL OF LIPID RESEARCH, 2002, 43 (09) :1363-1379

[4] Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients [J].

Bloomfield, Daniel ;

Carlson, Gary L. ;

Sapre, Aditi ;

Tribble, Diane ;

McKenney, James M. ;

Littlejohn, Thomas W., III ;

Sisk, Christine McCrary ;

Mitchel, Yale ;

Pasternak, Richard C. .

AMERICAN HEART JOURNAL, 2009, 157 (02) :352-U20

[5] Differences in receptor binding of LDL subfractions [J].

Campos, H ;

Arnold, KS ;

Balestra, ME ;

Innerarity, TL ;

Krauss, RM .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1996, 16 (06) :794-801

[6] Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. [J].

Cannon, Christopher P. ;

Shah, Sukrut ;

Dansky, Hayes M. ;

Davidson, Michael ;

Brinton, Eliot A. ;

Gotto, Antonio M., Jr. ;

Stepanavage, Michael ;

Liu, Sherry Xueyu ;

Gibbons, Patrice ;

Ashraf, Tanya B. ;

Zafarino, Jennifer ;

Mitchel, Yale ;

Barter, Philip .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (25) :2406-2415

[7] Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis [J].

Caulfield, Michael P. ;

Li, Shuguang ;

Lee, Gloria ;

Blanche, Patricia J. ;

Salarneh, Wael A. ;

Benner, W. Henry ;

Reitz, Richard E. ;

Krauss, Ronald M. .

CLINICAL CHEMISTRY, 2008, 54 (08) :1307-1316

[8] Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone [J].

Forrest, M. J. ;

Bloomfield, D. ;

Briscoe, R. J. ;

Brown, P. N. ;

Cumiskey, A-M ;

Ehrhart, J. ;

Hershey, J. C. ;

Keller, W. J. ;

Ma, X. ;

McPherson, H. E. ;

Messina, E. ;

Peterson, L. B. ;

Sharif-Rodriguez, W. ;

Siegl, P. K. S. ;

Sinclair, P. J. ;

Sparrow, C. P. ;

Stevenson, A. S. ;

Sun, S-Y ;

Tsai, C. ;

Vargas, H. ;

Walker, M., III ;

West, S. H. ;

White, V. ;

Woltmann, R. F. .

BRITISH JOURNAL OF PHARMACOLOGY, 2008, 154 (07) :1465-1473

[9]

FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499

[10] Torcetrapib Induces Aldosterone and Cortisol Production by an Intracellular Calcium-Mediated Mechanism Independently of Cholesteryl Ester Transfer Protein Inhibition [J].

Hu, Xiao ;

Dietz, Jessica D. ;

Xia, Chunsheng ;

Knight, Delvin R. ;

Loging, William T. ;

Smith, Andrew H. ;

Yuan, Haodan ;

Perry, David A. ;

Keiser, Joan .

ENDOCRINOLOGY, 2009, 150 (05) :2211-2219

← 1 2 3 →